GFP/Luc Reporter Cell Line - NCI-H1650

The NCI-H1650 cell line is a widely utilized human model of non-small cell lung cancer (NSCLC), originally derived from the pleural effusion of a patient with bronchoalveolar carcinoma. It is highly significant in thoracic oncology because it harbors an activating exon 19 deletion in the epidermal growth factor receptor (EGFR) gene alongside a concurrent PTEN homozygous deletion, making it a pivotal model for studying intrinsic resistance to targeted tyrosine kinase inhibitors. The GFP/Luc Reporter Cell Line - NCI-H1650 is a sophisticated, stably transfected derivative explicitly engineered to co-express both Green Fluorescent Protein (GFP) and firefly luciferase (Luc). This robust dual-labeling construct guarantees steady, high-level expression of both reporter genes across sequential in vitro passages without compromising the fundamental biological characteristics, unique molecular alterations, or intrinsic tumorigenic potential of the original parental cells.

The integration of this dual-reporter system dramatically expands the experimental utility of the NCI-H1650 model for complex translational lung cancer research. In vitro, the bright GFP fluorescence allows researchers to easily track cellular dynamics, precisely quantify proliferation, and isolate specific tumor subpopulations utilizing standard fluorescence microscopy and flow cytometry techniques. For in vivo applications, the strong luciferase expression serves as the foundation for non-invasive, longitudinal tracking of tumor progression and metastasis through bioluminescence imaging (BLI). As a human-derived cell line, the NCI-H1650-GFP/Luc model is typically engrafted into immunocompromised mice (such as athymic nude or NSG strains) to establish localized subcutaneous or orthotopic pulmonary xenografts. This specialized reporter line is exceptionally well-suited for evaluating novel therapeutic strategies aimed at overcoming TKI resistance, testing next-generation combinatorial treatments, and investigating the biological pathways driving NSCLC progression. By facilitating the real-time, accurate quantification of localized tumor burden and systemic spread in living subjects, it highly optimizes experimental workflows in preclinical precision oncology.